Join us on August 29, 2024 from 9-10am CT for the third episode of Series 1 of the ALZ-NET International Case Study Series, which will explore eligibility of patients for treatment.
Three cases will be discussed in Episode 3.
Presenter #1:
Eligibility for MAB: 70 year old with language variant AD. Borderline MMSE, but fully intact functionally. Apolipoprotein e4e4 genotype.
Eligibility for Brexpiprazole: 72 year old with gradual onset memory loss. MoCA 19/30, higher level functional changes, and verbal agitation.
Presenter #2:
Eligibility for MAB: 75 year old with mild cognitive impairment due to AD. CSF biomarkers abnormal including abeta 42/40. MRI showed ischemic microangiopathy. Apolipoprotein e4 non carrier. On a liquid for atrial fibrillation. CDR sum of boxes 0.5. CDR global 0.5. FAQ 1. MoCA 27/30.
Presenters: David Weisman, Margarita Reyes
Three cases will be discussed in Episode 3.
Presenter #1:
Eligibility for MAB: 70 year old with language variant AD. Borderline MMSE, but fully intact functionally. Apolipoprotein e4e4 genotype.
Eligibility for Brexpiprazole: 72 year old with gradual onset memory loss. MoCA 19/30, higher level functional changes, and verbal agitation.
Presenter #2:
Eligibility for MAB: 75 year old with mild cognitive impairment due to AD. CSF biomarkers abnormal including abeta 42/40. MRI showed ischemic microangiopathy. Apolipoprotein e4 non carrier. On a liquid for atrial fibrillation. CDR sum of boxes 0.5. CDR global 0.5. FAQ 1. MoCA 27/30.
Presenters: David Weisman, Margarita Reyes
Date & Time
Thursday August 29th, 2024 9:00am CDT
End Date & Time
Thursday August 29th, 2024 10:00am CDT
.png)